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Uveal melanoma is a life-threatening disease for which there is as yet no curative 
treatment. Once metastasis has occurred, the survival rate is very low. Little is known so 
far about the genetics underlying this malignancy. In particular, the relevance of 
mitogen-activated protein kinase (MAPK) pathway in the development of uveal 
melanomas remains unclear. While BRAF and NRAS mutations are a common event 
both in benign and malignant melanocytic neoplasms, uveal melanoma and other 
melanocytic neoplasms without epithelial association harbor no equivalent oncogenic 
events.  
This report presents novel data following the discovery of somatic mutations in the 
heterotrimeric G protein alpha q subunit (GNAQ), found in 44% of uveal melanomas, 
83% of blue nevi, and 50% of melanomas arising within blue nevi. GNAQ
Q209L
 activates 
the MAPK pathway, with levels of ERK phosphorylation comparable to a NRAS
Q61R 
- 
mutant condition. We showed that primary normal human melanocytes expressing 
GNAQ
Q209L
 exhibit phenotypical changes in cellular and nuclear morphology. 
Furthermore, introducing GNAQ
Q209L
 to immortalized melanocytes triggered 
anchorage-independent growth.  
Conversely, silencing GNAQ
Q209L
 by siRNA reduced colony formation in soft-agar and 
induced apoptosis in uveal melanoma cell lines carrying a GNAQ mutation. 
Investigating its downstream signaling, the Protein kinase C (PKC) family was identified 
as potential therapeutic targets. Phospho-PKCµ (P-PKD) and total PKC levels were 
found to be elevated in mutant-GNAQ expressing cells. Preliminary experiments using 
specific PKC inhibitors failed to reduce levels of P-PKD or induce apoptosis. Still, as 
siRNA against GNAQ
Q209L
 significantly decreased levels of P-PKD, and as notably high 
levels of P-PKD and total PKC were detected in patient-derived uveal melanoma cell 
lines carrying a GNAQ mutation, further investigation of these proteins as therapeutic 
targets is still warranted.  
Also, we were able to show that BRAF protein levels are higher in uveal melanoma cell 
lines with mutant GNAQ as measured by Western blot – while the analysis of a public 
data base suggests that BRAF expression levels are indeed high in uveal melanoma 
patients with GNAQ
 
mutation. 
Further experiments will be necessary to draw any final conclusion, but the pathway 
downstream of oncogenic GNAQ certainly bears important therapeutic potential, while 
the purport research could find translation into clinics relatively fast. 
 
